AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

Company Overview

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.49 to $0.86
• 52-Week Range: N/A
• Volume: 243,500 shs
• Average Volume: 137,683 shs
• Market Capitalization: $14.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

AcelRx Pharmaceuticals Stock Analysis - MarketRank™

AcelRx Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat, and ranked 730th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AcelRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AcelRx Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AcelRx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AcelRx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AcelRx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

AcelRx Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.41

Short Interest

There is no current short interest data available for ACRX.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.00% of the stock of AcelRx Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 19.79% of the stock of AcelRx Pharmaceuticals is held by institutions.

ACRX Stock Analysis - Frequently Asked Questions

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) EPS for the quarter, hitting the consensus estimate of ($1.40). The specialty pharmaceutical company earned $1.86 million during the quarter, compared to analysts' expectations of $1.20 million.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals's stock reverse split before market open on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ACRX
• CUSIP: N/A
• CIK: 1427925
• Web: www.acelrx.com
• Phone: (650) 216-3500
• Fax: 650-216-6500
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $47.76 million
• Net Margins: N/A
• Pretax Margin: -3,711.25%
• Return on Equity: -81.54%
• Return on Assets: -46.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.04
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: $1.77 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 16,950,000
• Free Float: 16,443,000
• Market Cap: $14.58 million
• Optionable: Optionable
• Beta: 0.52